IGF2BP3 as a Cancer and Testis Antigen and Potential Drug Target

Target Name: IGF2BP3

NCBI ID: G10643

IGF2BP3

IGF2BP3 as a Cancer and Testis Antigen and Potential Drug Target

The insulin-like growth factor 2 (IGF2) is a cytokine that plays a crucial role in the growth and development of various tissues, including cancer and testes. IGF2 has been identified as a potential drug target in cancer and testicular diseases due to its unique mechanism of action and its involvement in various biological processes. IGF2BP3, a non-coding RNA (ncRNA), has been identified as a potential IGF2-related protein that may serve as a drug target or biomarker for cancer and testicular diseases.

IGF2BP3: A Potential Drug Target

IGF2BP3 is a 21-kDa protein that is expressed in various tissues, including cancer and testes. It is a key component of the insulin-like growth factor signaling pathway, which is a complex network of proteins that regulate cellular growth, differentiation, and survival. IGF2BP3 functions as a negative regulator of the IGF2 signaling pathway, which inhibits the activity of the transcription factor, transforming growth factor beta (NF-kappa).

IGF2BP3 has been shown to play a crucial role in the regulation of cellular processes that are critical for cancer and testicular development. For instance, IGF2BP3 has been shown to inhibit the activity of NF-kappa, which is a key transcription factor that promotes the development of cancer cells. Additionally, IGF2BP3 has been shown to promote the degradation of the oncogene, p53, which is a critical negative regulator of cell growth and a key factor in the regulation of apoptosis.

Furthermore, IGF2BP3 has been shown to play a role in the regulation of testicular development and function. IGF2BP3 has been shown to promote the growth and development of testicular germ cells and to regulate the differentiation of these cells into functional testicular organs, such as the vas deferens. Additionally, IGF2BP3 has been shown to play a role in the regulation of testicular inflammation and immune tolerance.

In conclusion, IGF2BP3 is a protein that has been identified as a potential drug target for cancer and testicular diseases due to its involvement in the regulation of cellular processes that are critical for these conditions. Further research is needed to determine the full implications of IGF2BP3 as a drug target and to develop effective therapies for cancer and testicular diseases.

Protein Name: Insulin Like Growth Factor 2 MRNA Binding Protein 3

Functions: RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs

The "IGF2BP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGF2BP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets